A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interforn Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects: Boceprevir, Interferon, Ribavirin to Treat HCV/HIV/Coinfected Subjects (BIRTH)

Grant

Date/time Interval

  • March 1, 2012 - May 31, 2014
  • Total Award Amount

  • 415240.00
  • Direct Costs

  • 283440.00
  • Sponsor Award Id

  • BRS-ACURE-S-12-002461
  • Contributor

  • Johnson, Victoria   Principal Investigator